PUYO-GJP-N1: Original Clinical Hypotheses on Dawn Phenomenon, Nocturnal SGLT2i Strategy, and Ketogenic Nutrition in Type 2 Diabetes Mellitus — N=1 Self-Experimentation Protocol

Five original clinical hypotheses derived from a rigorous N=1 self-experimentation protocol in T2DM, combining ketogenic nutrition, continuous glucose monitoring, and pharmacological analysis. September 2025 – May 2026. Brest, France. Hypotheses PUYO-GJP-N1-H1 through H5 cover: dawn phenomenon as euDKA protective factor, dawn phenomenon as diagnostic confounding variable in T2DM, nocturnal SGLT2i as circadian precision monotherapy, SGLT2i ketone amplification in ketogenic context, and cost-benefit analysis of pharmacological optimization vs sustainable metabolic equilibrium. These hypotheses will be further documented in a forthcoming autobiographical book: "¿Cómo llegué hasta aquí? N=1: La crónica de mi equilibrio metabólico" by Georges José PUYO (planned publication 2026).French version available upon request. Spanish version forthcoming.